Laurie Glimcher, President and CEO of Dana-Farber Cancer Institute, shared on X/Twitter:
“Exciting news that Belzutifan is approved by the FDA based on a study led by Toni Choueiri, offering a new treatment option for patients with advanced kidney cancer previously treated with immune checkpoint inhibitors and anti-angiogenic therapies.”
To read the article click here.
Source: Laurie Glimcher/X